In pediatrics, dasatinib is approved for the treatment of Philadelphia chromosome-positive (Ph+) CML and Ph+ ALL. It is important for physicians to closely monitor pediatric patients for potential side effects and efficacy of the treatment. Dosage adjustments may be required based on the patient's response and tolerance.
